Vera Therapeutics (VERA) AI Stock Analysis

• Market Cap: $1.37B
• Dividend Yield: N/A
• Average Volume (3M): 953.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: N/A
• EPS Growth: -20.03%
• Country: US
• Employees: 112
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -2.74
• Shares Outstanding: 63,771,720
• 10 Day Avg. Volume: 1,413,713
• 30 Day Avg. Volume: 953,061
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 883.47
• Price to Cash Flow (P/CF): -11.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $67.20
• Price Target Upside: 212.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

Vera Therapeutics is in a high-risk biotech sector, with financial challenges and bearish technicals. However, positive corporate developments could offer future growth potential.

Positive Factors

Clinical Trials

Vera Therapeutics announced the completion of full enrollment for the Phase III ORIGIN 3 study, evaluating the safety and efficacy of atacicept in IgAN patients.

Market Opportunity

There is a large commercial opportunity in IgAN, with multiple winners expected in the BLyS and/or APRIL inhibitor class due to the disease-modifying potential of these treatments.

Product Differentiation

Atacicept is the only BLyS and/or APRIL inhibitor studied as a self-administered injection in both Phase II and III studies, with 90% patient retention at 2 years.

Negative Factors

Competitive Pressure

Vera experienced a significant sell-off following competitor Otsuka's announcement about their plans to file for a competing treatment.

Regulatory Risk

There is regulatory risk and uncertainty regarding Otsuka’s strategy for sibeprenlimab, which impacts the competitive landscape.

Vera Therapeutics Business Overview & Revenue Model

Company Description

Vera Therapeutics (VERA) is a biotechnology company focused on developing transformative treatments for serious immunological diseases. With a strong emphasis on research and development, the company's core product pipeline includes innovative therapies aimed at addressing unmet needs in the treatment of kidney diseases and other immune-related conditions.

How the Company Makes Money

Vera Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, research collaborations, and eventually, sales of approved therapies. Key revenue streams involve upfront payments, milestone payments, and royalties from commercial partnerships with larger pharmaceutical companies. Significant partnerships with industry leaders and research organizations play a crucial role in advancing their drug development programs and contributing to potential future earnings.

Vera Therapeutics Financial Statement Overview

Summary

Vera Therapeutics is in a challenging phase, marked by consistent net losses and negative cash flows. Despite a low debt-to-equity ratio and some positive trends in equity, the company faces significant financial instability due to its ongoing losses and cash management issues.

Income Statement

Vera Therapeutics has faced a challenging period with consistent net losses and negative EBIT margins over the years. The absence of revenue growth and a significant increase in net losses highlight financial instability. However, the improvements in gross profit from negative to positive values in recent years offer a slight positive trajectory.

Balance Sheet

The company demonstrates a strong equity position with a growing stockholders' equity, minimizing debt leverage. The debt-to-equity ratio remains low, indicating prudent financial management. However, the overall equity ratio has fluctuated, reflecting potential volatility in asset management.

Cash Flow

Vera Therapeutics experiences negative free cash flows, with operating cash flow consistently below net income, highlighting cash management challenges. A positive note is the significant financing inflows that bolster cash reserves, although relying on financing isn't sustainable long-term.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	1.86M	0.00	0.00	0.00
	Gross Profit
0.00	1.86M	846.00K	-176.00K	-251.00K
	EBIT
-167.17M	-102.01M	-90.90M	-34.40M	-52.24M
	EBITDA
-167.17M	-102.01M	-90.90M	-34.23M	-52.99M
	Net Income Common Stockholders
-152.15M	-95.99M	-89.06M	-32.61M	-53.41M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
640.85M	160.72M	114.65M	79.67M	53.65M
	Total Assets
655.68M	175.55M	131.44M	83.75M	54.55M
	Total Debt
54.64M	53.71M	31.29M	4.92M	2.00K
	Net Debt
-38.01M	8.03M	-83.37M	-74.75M	-53.65M
	Total Liabilities
78.53M	73.86M	54.53M	14.16M	143.90M
	Stockholders Equity
577.15M	101.69M	76.91M	69.59M	-89.35M
Cash Flow		Free Cash Flow
-135.65M	-92.24M	-67.66M	-23.71M	-34.91M
	Operating Cash Flow
-134.68M	-92.18M	-67.60M	-23.71M	-34.81M
	Investing Cash Flow
-425.03M	-39.43M	-70.55M	-4.20M	-42.00K
	Financing Cash Flow
606.67M	133.54M	101.93M	53.88M	85.29M

Vera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 21.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Negative. The current price of 21.5 is below the 20-day moving average (MA) of 23.87, below the 50-day MA of 27.84, and below the 200-day MA of 37.32, indicating a bearish trend. The MACD of -2.03 indicates Negative momentum. The RSI at 38.02 is Neutral, neither overbought nor oversold. The STOCH value of 62.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERA.

Vera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCR	59 Neutral	$1.35B	―	-13.92%	―	24.19%	10.51%
KYMR	50 Neutral	$1.65B	―	-36.38%	―	-40.11%	-17.79%
NAMS	48 Neutral	$1.80B	―	-61.35%	―	―	―
Sector *	48 Neutral	$6.46B	1.17	-48.25%	2.67%	19.50%	0.61%
TVTX	44 Neutral	$1.32B	―	-246.75%	―	17.27%	10.01%
VERA	41 Neutral	$1.37B	―	-44.83%	―	―	-20.03%
IRON	41 Neutral	$1.39B	―	-27.73%	―	―	-14.19%

Vera Therapeutics Corporate Events

Vera Therapeutics Highlights Atacicept Progress at Conference

Vera Therapeutics announced an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting the progress of their lead therapy, atacicept, in clinical trials. The company is positioned strongly with $677 million in cash and marketable securities, and is focused on potential commercial launch plans, bolstered by breakthrough therapy designation from the FDA for atacicept in treating IgAN. The company aims to expand atacicept’s indications to other autoimmune and kidney diseases, with several clinical trials underway.